-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, November 4, 2021/PRNewswire/ - Recently, the "Chinese Anti-Cancer Association Guidelines and Specifications for Breast Cancer Diagnosis and Treatment (2021 Edition)" (hereinafter referred to as the CACA-CBCS "Guide") was officially released
According to statistics from the International Agency for Research on Cancer (IARC) of the World Health Organization, breast cancer surpassed lung cancer for the first time in 2020, becoming the world's most cancerous cancer
Inituzumab is China's first innovative anti-HER2 monoclonal antibody with Fc segment modification, optimized production process, and stronger ADCC effect
The results of the HOPES study showed that initumumab plus chemotherapy for HER2-positive metastatic breast cancer patients who had previously received one or more chemotherapy regimens, compared with chemotherapy alone, can prolong the median progression-free survival of the primary endpoint (mPFS, 39.
Initumab was approved for marketing by NMPA in June 2020 and entered the national medical insurance in the same year
Professor Zhang Jian from the Cancer Hospital of Fudan University said: “We look forward to the continued expansion of the indications for Inituzumab.
Source: Sansheng Guojian